Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Jul 12, 2021 at 11:00 AM EDTH.C. WAINWRIGHT FIRESIDE CHAT WITH PHIO PHARMACEUTICALS
Jun 17, 2021AGP SUMMER HEALTHCARE SYMPOSIUM
Jun 4 - Jun 8, 2021The 2021 American Society of Clinical Oncology (ASCO) Annual Meeting